Does Pea Protein Satiety Meta-Analysis work?

The current Migaku evidence database contains 2 reusable source documents for Pea Protein Satiety Meta-Analysis. This answer focuses on strength of evidence and what the studies can or cannot prove. - to manage postprandial glycaemic excursions, such as hyperglycaemia— a key risk factor for cardiometabolic complications. [Elbira Arig (2026); evidence level 2] - Elevated postprandial glucose levels are consistently associated with increased cardiovascular risk, even in normoglycaemic individuals []. [Elbira Arig (2026); evidence level 2] - found that whey protein preloads significantly reduced peak glucose (− 0.62 mmol/L) and 2-hour iAUC (− 39.8 mmol·min/L), particularly with doses ≥ 20 g taken 15–30 min before a carbohydrate-rich meal []. [Elbira Arig (2026); evidence level 2] - 1 3 4 The increasing prevalence of metabolic disorders and cardiovascular diseases presents significant challenges to global health [–], highlighting the need for cost-effective dietary interventions e.g. [Elbira Arig (2026); evidence level 2] - According to the internationally used definition, MetS is characterized by having at least three out of several possible risk factors, including high blood pressure, hypertriglyceridemia, low levels of HDL cholesterol, elevated fasting glucose, and central obesity (). [Wang Song-nan (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.